Here are four things to know.
1. The new drugs offer treatments for cancer, depression and the flu, among others.
2. J&J plans to launch or submit the new treatments for regulatory approval within the next four years.
3. The drugmaker will also work to expand the approved uses of more than 50 current product lines, according to William Hait, research chief of J&J’s Janssen research and development division.
4. The announcement marks a major push in product development for the company. From 2009 to 2015, J&J only commercialized seven drugs topping $1 billion in annual sales, according to USA Today.
More articles on supply chain:
Viewpoint: Why healthcare needs more ‘me too’ drugs
Viewpoint: Pharma should give trial participants a say in pricing new drugs
Magellan vein-based blood tests underreported lead levels, says health officials
